Abacus Medicine
Abacus Medicine, a leading player in the pharmaceutical industry, is headquartered in Denmark (DK) and operates extensively across Europe. Founded in 2004, the company has established itself as a key provider of parallel-imported medicines, ensuring access to high-quality pharmaceuticals at competitive prices. Abacus Medicine's core services include sourcing, distributing, and supplying a wide range of prescription medications, with a focus on efficiency and compliance with regulatory standards. The company is renowned for its commitment to quality assurance and has achieved significant milestones, including partnerships with major healthcare providers. With a strong market position, Abacus Medicine continues to innovate in the pharmaceutical supply chain, making it a trusted name in the industry. Its unique approach to parallel imports not only enhances accessibility but also contributes to cost savings for healthcare systems across its operational regions.
DitchCarbon Score
How does Abacus Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abacus Medicine's score of 32 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abacus Medicine's reported carbon emissions
In 2024, Abacus Medicine reported total carbon emissions of approximately 553,400 kg CO2e, comprising 235,300 kg CO2e from Scope 1 and 318,100 kg CO2e from Scope 2 (market-based). This marks a slight increase in Scope 1 emissions from 216,900 kg CO2e in 2023, while Scope 2 emissions decreased from 642,600 kg CO2e in the previous year. Over the past few years, the company has shown fluctuations in its emissions, with Scope 1 emissions peaking at 239,000 kg CO2e in 2021 and Scope 2 emissions reaching a high of 664,400 kg CO2e in the same year. Notably, the total emissions for 2023 were approximately 859,500 kg CO2e, indicating a need for ongoing efforts to manage and reduce their carbon footprint. Abacus Medicine has not disclosed any specific reduction targets or initiatives, nor does it report on Scope 3 emissions. The data is cascaded from its parent company, Abacus Medicine A/S, reflecting the company's commitment to transparency in its sustainability reporting. As a current subsidiary, Abacus Medicine is part of a broader corporate family that may influence its climate strategies, although specific initiatives or targets from the parent organisation have not been detailed. The company continues to monitor its emissions and is expected to align with industry standards for climate action in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 62,600 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | - | - | - | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abacus Medicine is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
